开发用于估算丙型肝炎抗病毒治疗后肝细胞癌风险的模型
研究基于美国退伍军人事务部国家医疗系统2009年1月1日至2015年12月31日启动抗病毒治疗的45810例丙型肝炎患者,其中29309例(64%)仅用直接抗病毒药物方案,16501例(36%)用于干扰素±直接抗病毒药物方案,回顾性随访至2017年6月15日,平均随访2.5年(范围1.0-7.5年),发现1412例肝细胞癌 incident 病例,分别针对肝硬化/持续病毒学应答、肝硬化/无持续病毒学应答、无肝硬化/持续病毒学应答、无肝硬化/无持续病毒学应答四个亚组开发并内部验证了肝细胞癌风险预测模型,模型校准良好且区分度很好,决策曲线显示基于模型的风险估算在决定是否推荐筛查方面比全员筛查或全员不筛查策略有更高的净获益。
要点
- 基于年龄、血小板计数、天冬氨酸氨基转移酶/√丙氨酸氨基转移酶比值和白蛋白四个预测因子构建的模型涵盖大部分预测价值。
- 模型按肝硬化状态和持续病毒学应答状态分四个亚组分别开发并内部验证。
- 决策曲线显示使用模型估算风险决定是否筛查比全员筛查或全员不筛查策略净获益更高。
核心结论
- 开发并内部验证了估算抗病毒治疗后肝细胞癌风险的模型,模型以网络工具形式提供,可用于指导个体患者的风险导向肝细胞癌监测策略。
研究设计与样本
- 回顾性队列研究,纳入2009年1月1日至2015年12月31日在美国退伍军人事务部国家医疗系统启动抗病毒治疗的45810例患者,其中29309例(64%)仅用直接抗病毒药物方案,16501例(36%)用于干扰素±直接抗病毒药物方案,随访至2017年6月15日。
- 使用Cox比例风险回归开发并内部验证预测肝细胞癌风险的模型,预测因子为抗病毒治疗时的基线特征。
主要发现
- 平均随访2.5年(范围1.0-7.5年)期间,发现1412例在启动抗病毒治疗至少180天后诊断的肝细胞癌 incident 病例。
- 四个预测因子(年龄、血小板计数、血清天冬氨酸氨基转移酶/√丙氨酸氨基转移酶比值和白蛋白)涵盖模型大部分预测价值,性别、种族-民族、丙型肝炎病毒基因型、体重指数、血红蛋白和血清甲胎蛋白贡献较小。
- 拟合模型校准良好且区分度很好;决策曲线显示使用基于模型的风险估算决定是否推荐筛查比全员筛查或全员不筛查策略净获益更高。
关键数值与推荐
- 模型分别针对四个亚组开发并验证:肝硬化/持续病毒学应答、肝硬化/无持续病毒学应答、无肝硬化/持续病毒学应答、无肝硬化/无持续病毒学应答。
临床怎么用
- 模型以网络工具形式提供,可用于指导个体患者的风险导向肝细胞癌监测策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Most patients with hepatitis C virus (HCV) infection will undergo antiviral treatment with direct-acting antivirals (DAAs) and achieve sustained virologic response (SVR). We aimed to develop models estimating hepatocellular carcinoma (HCC) risk after antiviral treatment. METHODS: We identified 45,810 patients who initiated antiviral treatment in the Veterans Affairs (VA) national healthcare system from 1/1/2009 to 12/31/2015, including 29,309 (64%) DAA-only regimens and 16,501 (36%) interferon ± DAA regimens. We retrospectively followed patients until 6/15/2017 to identify incident cases of HCC. We used Cox proportional hazards regression to develop and internally validate models predicting HCC risk using baseline characteristics at the time of antiviral treatment. RESULTS: We identified 1,412 incident cases of HCC diagnosed at least 180 days after initiation of antiviral treatment during a mean follow-up of 2.5 years (range 1.0-7.5 years). Models predicting HCC risk after antiviral treatment were developed and validated separately for four subgroups of patients: cirrhosis/SVR, cirrhosis/no SVR, no cirrhosis/SVR, no cirrhosis/no SVR. Four predictors (age, platelet count, serum aspartate aminotransferase/√alanine aminotransferase ratio and albumin) accounted for most of the models' predictive value, with smaller contributions from sex, race-ethnicity, HCV genotype, body mass index, hemoglobin and serum alpha-fetoprotein. Fitted models were well-calibrated with very good measures of discrimination. Decision curves demonstrated higher net benefit of using model-based HCC risk estimates to determine whether to recommend screening or not compared to the screen-all or screen-none strategies. CONCLUSIONS: We developed and internally validated models that estimate HCC risk following antiviral treatment. These models are available as web-based tools that can be used to inform risk-based HCC surveillance strategies in individual patients. LAY SUMMARY: Most patients with hepatitis C virus have been treated or will be treated with direct-acting antivirals. It is important that we can model the risk of hepatocellular carcinoma in these patients, so that we develop the optimum screening strategy that avoids unnecessary screening, while adequately screening those at increased risk. Herein, we have developed and validated models that are available as web-based tools that can be used to guide screening strategies.
引用
- Ioannou GN, Green PK, Beste LA, et al. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018. PMID: 30138686. doi:10.1016/j.jhep.2018.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。